Volume 87 Issue 16 | pp. 21-24
Issue Date: April 20, 2009

Paying Attention To Neglected Diseases

The Drugs for Neglected Diseases Initiative is mobilizing public/private partnerships
Department: Business

IN FEBRUARY, when Andrew Witty, chief executive officer of GlaxoSmithKline, announced measures his company would take to develop and offer drugs for neglected diseases in the poorest countries, he received a lukewarm response from Médecins sans Frontières (Doctors Without Borders). The Nobel Prize-winning activist group criticized what it called a lack of details, adding that the patent pool Witty proposed should also include intellectual property (IP) related to HIV/AIDS.

Although the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society